Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tivozanib Communications Come Back To Haunt Aveo, Former Execs

Executive Summary

Company pays $4m to settle SEC claims that it failed to publicly disclose FDA's May 2012 recommendation for a new trial of its tyrosine kinase inhibitor, the subject of a negative advisory committee review a year later. Fraud claims against three former officers continue.

Advertisement

Related Content

Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer
Approval Or New Study? That’s The Question For Tivozanib Panel Review

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel